Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Completed · Phase 1

Conditions studied: Androgenetic Alopecia

In brief

This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).

Key facts

Study ID

NCT02848300

Run by

Allergan

People needed

11

Starts

2016-07-01

Expected to finish

2016-10-01

Last updated by the study team

2016-10-26

Who can join

Age: 18 and older, up to 49. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with mild to moderate Androgenetic Alopecia of the vertex area of the scalp.

You may not qualify if…

• Patients with uncontrolled systemic disease
• History of significant cardiovascular disease
• Scarring disease, infection, or abnormality of the scalp or hair shaft or systemic disease that could cause temporary hair loss (eg, seborrheic dermatitis, psoriatic dermatitis, alopecia areata, cicatricial alopecia, uncontrolled hyperthyroidism/hypothyroidism, tinea infections, and genetic disorders)
• Patients who have received hair transplants or have had scalp reductions
• Abnormal bone biomarker laboratory results.

Where it is running

• DermResearch, LLC — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.